Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
ESMO 2024: Recommendations From Dr. Oliver Sartor for Prostate Cancer
- Written by
-
Oliver
Sartor
MD
Dr. Oliver Sartor, Chair of the Genitourinary Cancer Disease Group at the, Mayo Clinic in Rochester, Minnesota, and a member of the Advisory Board for PracticeUpdate Oncology, recommends the following abstracts to be presented at this year's ESMO Congress, held September 13 through 17, 2024, in Barcelona.
Saturday, September 14, 2024
4:30 PM–6:15 PM CEST; Presidential Symposium I
LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3. S Gillessen
Sunday, September 15, 2024
2: 45 PM–3:15 PM CEST; Proffered Paper Session
LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). O Sartor
Monday, September 16, 2024
10:15 AM–11:45 AM CEST; Mini Oral Session
LBA68 Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial. F Saad
Additional Info
Disclosure statements are available on the authors' profiles:
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.